Literature DB >> 24147831

Impact of occluded culprit arteries on long-term clinical outcome in patients with non-ST-elevation myocardial infarction: 48-month follow-up results in the COREA-AMI Registry.

Dong Il Shin1, Kiyuk Chang, Youngkeun Ahn, Byung-Hee Hwang, Hun-Jun Park, Seok Min Seo, Yoon-Seok Koh, Pum-Joon Kim, Ki-Bae Seung, Myung Ho Jeong.   

Abstract

BACKGROUND: The prognostic impact of occluded culprit arteries in non-ST-elevation myocardial infarction (NSTEMI) patients beyond 12 months has not been investigated.
OBJECTIVES: The impact of occluded culprit arteries on a composite of cardiac death (CD), recurrent nonfatal MI (RMI), and target vessel revascularization (TVR) in patients who presented with NSTEMI was investigated during a 48-month follow-up using propensity-score (PS) matching.
METHODS: A total of 2,878 NSTEMI patients in the COREA-AMI (COnvergent REgistry of cAtholic and chonnAm university for Acute MI) Registry were classified according to the angiographic flow of culprit arteries (occlusion [OC], n = 1,070; nonocclusion, n = 1,808). After PS matching, the incidence of the primary end-point, a composite of CD, RMI, and TVR was compared.
RESULTS: The median follow-up duration was 47.3 months (IQR 32.7-66.2). In the PS-matched population, the 48-month cumulative rates of the primary end-point (27.5% vs. 17.9%, P < 0.001) and each event were higher in the OC group (CD: 9.0% vs. 5.4%, RMI: 16.3% vs. 9.4%, TVR: 10.5% vs. 5.6%, respectively, P < 0.05). In multivariate Cox regression analysis, occluded culprit arteries showed the significant statistical impact on the primary end-point (HR 1.689 [1.385-2.059], P < 0.001) and each event (CD: 1.736 [1.218-2.475], RMI: 1.918 [1.468-2.505], TVR: 2.042 [1.453-2.869], respectively, P < 0.05). Furthermore, in the 12-month landmark analysis, occluded culprit arteries were still associated with higher risk of primary end-point beyond 12 months (P < 0.001).
CONCLUSIONS: Occluded culprit arteries were independently associated with the higher risk of CD, RMI, and TVR in NSTEMI patients during the 48-month follow-up.
© 2013, Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24147831     DOI: 10.1111/joic.12078

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  5 in total

1.  Clinical characteristics of occluded culprit arteries and collaterals in patients with non-ST-segment elevation myocardial infarction and impact on clinical outcomes.

Authors:  Hui-Jeong Hwang; Chang-Bum Park; Jin-Man Cho; Eun-Sun Jin; Il Suk Sohn; Dong-Hee Kim; Chong-Jin Kim
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

2.  Incidence and impact of totally occluded culprit coronary artery in patients with non-ST segment elevation myocardial infarction acute coronary syndrome.

Authors:  Sherif W Ayad; Tarek H El Zawawy; Mohamed I Lotfy; Ahmed M Naguib; Ahmed M El Amrawy
Journal:  Egypt Heart J       Date:  2021-04-07

Review 3.  Prevalence and outcome of patients with non-ST segment elevation myocardial infarction with occluded "culprit" artery - a systemic review and meta-analysis.

Authors:  Chi-Sheng Hung; Ying-Hsien Chen; Ching-Chang Huang; Mao-Shin Lin; Chih-Fan Yeh; Hung-Yuan Li; Hsien-Li Kao
Journal:  Crit Care       Date:  2018-02-09       Impact factor: 9.097

4.  Acute Occlusion of the Infarct-Related Artery as a Predictor of Very Long-Term Mortality in Patients with Acute Myocardial Infarction.

Authors:  Nikola Kos; Ivan Zeljković; Tomislav Krčmar; Karlo Golubić; Fran Šaler; Marijan Erceg; Diana Delić-Brkljačić; Nikola Bulj
Journal:  Cardiol Res Pract       Date:  2021-11-24       Impact factor: 1.866

5.  The Spatial Distribution of Plaque Vulnerabilities in Patients with Acute Myocardial Infarction.

Authors:  Guian Zheng; Yuxin Li; Tadateru Takayama; Toshihiko Nishida; Mitsumasa Sudo; Hironori Haruta; Daisuke Fukamachi; Kimie Okubo; Yoshiharu Higuchi; Takafumi Hiro; Satoshi Saito; Atsushi Hirayama
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.